ADCT vs. IMTX, ORIC, RAPP, SEPN, PGEN, STOK, CGEM, AUTL, VALN, and XERS
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), Precigen (PGEN), Stoke Therapeutics (STOK), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), Valneva (VALN), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.
ADC Therapeutics vs.
ADC Therapeutics (NYSE:ADCT) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking.
In the previous week, ADC Therapeutics had 1 more articles in the media than Immatics. MarketBeat recorded 2 mentions for ADC Therapeutics and 1 mentions for Immatics. ADC Therapeutics' average media sentiment score of 0.97 beat Immatics' score of -0.26 indicating that ADC Therapeutics is being referred to more favorably in the media.
41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
ADC Therapeutics received 28 more outperform votes than Immatics when rated by MarketBeat users. However, 75.00% of users gave Immatics an outperform vote while only 67.44% of users gave ADC Therapeutics an outperform vote.
Immatics has lower revenue, but higher earnings than ADC Therapeutics. Immatics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
ADC Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 389.30%. Immatics has a consensus target price of $16.67, indicating a potential upside of 262.32%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Immatics.
ADC Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Immatics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
Immatics has a net margin of -47.94% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat Immatics' return on equity.
Summary
ADC Therapeutics beats Immatics on 10 of the 19 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:ADCT) was last updated on 2/22/2025 by MarketBeat.com Staff
